ストックスクリーナーアプリを入手
0.4865
0.98%
-0.0048
前日終値:
$0.4913
開ける：
$0.5
24時間の取引高:
44,455
Relative Volume:
0.34
時価総額：
$5.22M
収益：
-
当期純損益:
$-3.28M
株価収益率:
-0.4675
EPS:
-1.0406
ネットキャッシュフロー:
$-4.80M
1週間 パフォーマンス:
-5.53%
1か月 パフォーマンス:
-19.05%
6か月 パフォーマンス:
-29.78%
1年 パフォーマンス:
-47.90%
1日の値動き範囲:
$0.4855
$0.5009
1週間の範囲:
$0.4702
$0.5298
52週間の値動き範囲:
$0.4702
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
名前
Pharmacyte Biotech Inc
セクター
電話
(917) 595.2850
住所
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs PSNYW, GOODO, SHMD, DWLD, QQQE
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
5.00 | 394.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.15 | 315.90M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.39 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
120.75 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc (PMCB) 最新ニュース
PMCB Q1 2026 Earnings: Clinical-Stage Biotech Posts -$0.09 EPS with No RevenueSegment Revenue Breakdown - vinanet.vn
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportFundamentals - dars.gov.et
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71%Change of Character - vinanet.vn
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.57 Support Amid Minimal Price MovementSMA Signal - vinanet.vn
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Revenue-less Biotech Posts Net Loss; Stock SlipsEarnings Miss Alert - dars.gov.et
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Edges Lower Near Support; Key Levels in FocusLong Short Pair - vinanet.vn
PMCB Q1 2026 Earnings: Continued Development Costs Weigh on Results, No Revenue ReportedEarnings Season Outlook - vinanet.vn
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60High Dividend Factor - vinanet.vn
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
PharmaCyte Biotech (PMCB) Faces Near-Term Pressure, Testing Key Support at $0.60Tick Index - vinanet.vn
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
PMCB Q1 2026 Earnings: Losses Narrow as Biotech Advances Pipeline Amid Positive Market SentimentROA Comparison - Bölüm Sonu Canavarı
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Loss Per Share of $0.09 as Clinical Pipeline AdvancesEarnings Quality Score - po-news-eg.net
PharmaCyte Biotech | DEF 14A: Definitive information statements - Moomoo
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Continued Pre‑Revenue Losses as Pipeline Development Drives Net LossEstimate Accuracy - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Call Highlights - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMCB Q1 2026 Earnings: Reported Loss of -$0.09 Per Share as Stock DeclinesAnalyst Consensus Shift - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss, Shares Slide 8%Strong Earnings Momentum - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Q1 2026 Earnings: Modest Loss Reported Amid Early-Stage DevelopmentEarnings Surprise Report - dars.gov.et
Pharmacyte Biotech Inc (PMCB) 財務データ
収益
当期純利益
現金流量
EPS
Pharmacyte Biotech Inc (PMCB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President |
Jan 06 '26 |
Buy |
0.79 |
30,000 |
23,667 |
376,250 |
| Silverman Joshua | CEO and President |
Jan 05 '26 |
Buy |
0.78 |
30,000 |
23,493 |
346,250 |
| SCHECHTER JONATHAN | Director |
Jan 07 '26 |
Buy |
0.84 |
20,000 |
16,872 |
192,500 |
| SCHECHTER JONATHAN | Director |
Jan 06 '26 |
Buy |
0.79 |
20,000 |
15,808 |
172,500 |
| SCHECHTER JONATHAN | Director |
Jan 05 '26 |
Buy |
0.78 |
20,000 |
15,552 |
152,500 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):